<html>

<head>
<meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
<meta http-equiv="Content-Language" content="en-us">
<!-- #BeginEditable "doctitle" --> 
<title>CDC - Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations 
in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance</title>
<meta name="KEYWORDS" content="fluoroquinolone resistance, levofloxacin resistance, antimicrobial 
        susceptibility testing, topoisomerase">
<!-- #EndEditable --> 
<script language="JavaScript">
<!-- hide from non-JavaScript Browsers; 

function stopError(){
return true;
}
window.onerror = stopError;

bVer = parseInt(navigator.appVersion);

//end script -->
</script>
<script language="JavaScript" src="/ncidod/eid/eidscript.js">
</script>
</head>
<body bgcolor="#ffffff" leftmargin="0" topmargin="0" marginheight="0" marginwidth="0">
<table border="0" width="100%" cellspacing="0" cellpadding="0">
  <tr> 
    <td colspan="7" bgcolor="#000099"> <a href="#content_area"><img src="http://www.cdc.gov/navimages/spacer.gif" border="0" width="100%" height="1" alt="Skip Standard Navigation Links"></a></td>
  </tr>
  <tr> 
    <td width="140" valign="top" rowspan="2" bgcolor="#CCCCCC"> 
      <table border="0" cellpadding="0" cellspacing="0" width="140" bgcolor="#FFFFFF">
        <tr> 
          <td width="140"><a href="http://www.cdc.gov/"><img src="http://www.cdc.gov/navimages/nav11.gif" border="0" alt="Centers for Disease Control and Prevention" width="140" height="60"></a></td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" width="140">
        <tr> 
          <td width="140"><a href="http://www.cdc.gov/"><img src="http://www.cdc.gov/navimages/nav21.gif" border="0" width="140" height="8" alt=" "></a></td>
        </tr>
      </table>
    </td>
    <td width="12" valign="top" rowspan="2"><a href="http://www.cdc.gov/"><img border="0" src="http://www.cdc.gov/navimages/nav12.gif" alt=" " width="12" height="63"></a></td>
    <td width="267" height="19" valign="top"><a href="http://www.cdc.gov/"><img border="0" src="http://www.cdc.gov/navimages/nav13.gif" alt="CDC Home" width="267" height="19"></a></td>
    <td width="58" height="19" valign="top"><a href="http://www.cdc.gov/search.htm"><img border="0" src="http://www.cdc.gov/navimages/nav14.gif" alt="Search" width="58" height="19"></a></td>
    <td width="118" height="19" valign="top"><a href="http://www.cdc.gov/health/diseases.htm"><img border="0" src="http://www.cdc.gov/navimages/nav15.gif" alt="Health Topics A-Z" width="118" height="19"></a></td>
    <td bgcolor="#000099" width="50%" height="19" valign="top"><img src="http://www.cdc.gov/navimages/spacer.gif" width="1" height="1" alt=" "></td>
    <td bgcolor="#000099" width="50%" height="19" valign="top"><img src="http://www.cdc.gov/navimages/spacer.gif" width="1" height="1" alt=" "></td>
  </tr>
  <tr> 
    <td width="99%" valign="top" colspan="5"> <!-- #BeginLibraryItem "/Library/header.lbi" --><table border="0" cellpadding="0" cellspacing="0" width="99%">
        <tr> 
          <td rowspan="2"><img src="../images/peer-reviewed.gif" alt="peer-reviewed.gif (582 bytes)" width="443" height="18"></td>
          <td width="50%"><img src="../images/spacer.gif" width="1" height="16" alt=" "></td>
          <td width="50%"><img src="../images/spacer.gif" width="1" height="16" alt=" "></td>
        </tr>
        <tr> 
          <td bgcolor="#000080" width="50%"><img src="../images/spacer.gif" alt=" " width="1" height="2"></td>
          <td bgcolor="#000080" width="50%"><img src="../images/spacer.gif" alt=" " width="1" height="2"></td>
        </tr>
        <tr> 
          <td><img src="../images/eid_header.gif" alt="eid_header.gif (2942 bytes)" width="443" height="26"></td>
          <td width="50%"><img src="../images/spacer.gif" width="1" height="26" alt=" "></td>
          <td width="50%"><img src="../images/spacer.gif" width="1" height="26" alt=" "></td>
        </tr>
        <tr> 
          <td rowspan="2"> <img border="0" src="../images/second_navbar2.gif" width="443" height="16"></td>
          <td bgcolor="#000080" width="50%"><img src="../images/spacer.gif" width="1" height="2" alt=" "></td>
          <td bgcolor="#000080" width="50%"><img src="../images/spacer.gif" width="1" height="2" alt=" "></td>
        </tr>
        <tr> 
          <td width="50%"><img src="../images/spacer.gif" width="1" height="14" alt=" "></td>
          <td width="50%"><img src="../images/spacer.gif" width="1" height="14" alt=" "></td>
        </tr>
      </table><!-- #EndLibraryItem --></td>
  </tr>
</table>
<table width="98%" border="0" cellspacing="0" cellpadding="0">
  <tr> 
    <td width="140" bgcolor="#CCCCCC" valign="top"><!-- #BeginEditable "left_nav" --> 
      <!-- #BeginLibraryItem "/Library/issue_id-vol9no7.lbi" -->
<table border="0" width="130" cellspacing="0" cellpadding="2" height="42" align="center">
  <tr>     
    <td height="38"><font face="Verdana, Arial, Helvetica" size="2"><b>Past Issue</b></font><br>
            <img src="/ncidod/eid/images/short_line.gif" alt=" " vspace="2" width="120" height="2"><br>
      <font face="Verdana, Arial, Helvetica" size="1"><b>Vol. 9, No. 7<br>
      July 2003</b></font></td>
        </tr>
      </table><!-- #EndLibraryItem --><!-- #EndEditable --><img src="../images/spacer.gif" width="140" height="1" alt=" "></td>
    <td width="12"><a name="#content_area"></a><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%" valign="top"> 
      <p><!-- #BeginLibraryItem "/Library/header_menu.lbi" --><strong><font face="Verdana, Arial, Helvetica" size="1"><a href="/ncidod/EID/index.htm">EID 
Home</a> | <a href="/ncidod/EID/upcoming.htm">Ahead of Print</a> | <a href="/ncidod/EID/pastcon.htm">Past 
Issues</a> | <a href="/ncidod/EID/search.htm">EID Search</a> | <a href="/ncidod/EID/feedback.htm">Contact 
Us</a> | <a href="/ncidod/EID/announc.htm">Announcements</a> | <a href="/ncidod/EID/citation.htm">Suggested 
Citation</a> | <a href="http://mc.manuscriptcentral.com/eid/" target="_blank">Submit Manuscript</a></font></strong><!-- #EndLibraryItem --> 
      </p>
      <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><a href="pdfs/02-0589.pdf">PDF 
        Version</a></b> | <b><a href="/ncidod/eid/download.htm">Download Adobe 
        Acrobat</a></b> | <b><a href="#com">Comments</a></b> | <a href="#email"><img src="../images/email.gif" width="14" height="9" border="0" align="bottom" alt="Email this article"></a> 
        <a href="#email"><b>Email this article</b></a></font> </p>
      <table width="100%" border="0" cellspacing="0" cellpadding="0">
        <tr> 
          <td width="100%"><img src="../images/spacer.gif" width="1" height="8" alt=" "></td>
        </tr>
      </table>
      <!-- #BeginEditable "content_area_1" --><!-- #EndEditable --></td>
  </tr>
</table>
<table width="98%" border="0" cellspacing="0" cellpadding="0">
  <tr> 
    <td width="140" bgcolor="#CCCCCC" valign="top"><img src="../images/spacer.gif" width="140" height="1" alt=" "><br>
      <!-- #BeginEditable "titles" --> 
      <table border="0" width="130" cellspacing="0" cellpadding="2" align="center">
        <tr> 
          <td colspan="2"><img src="http://www.cdc.gov/navimages/spacer.gif" width="2" height="12" alt=" "><br>
            <font face="Verdana, Arial, Helvetica" size="1"></font></td>
        </tr>
        <tr> 
          <td width="10" valign="baseline" align="left"> <font size="1" face="Verdana, Arial, Helvetica" color="#000099">&#149;</font></td>
          <td width="125" valign="top" align="left"><a href="#met"><font face="Verdana, Arial, Helvetica" size="1">Materials 
            and Methods</font></a></td>
        </tr>
        <tr> 
          <td width="10" valign="baseline" align="left"> <font size="1" face="Verdana, Arial, Helvetica" color="#000099">&#149;</font></td>
          <td width="125" valign="top" align="left"><a href="#res"><font face="Verdana, Arial, Helvetica" size="1">Results</font></a></td>
        </tr>
        <tr> 
          <td width="10" valign="baseline" align="left"> <font size="1" face="Verdana, Arial, Helvetica" color="#000099">&#149;</font></td>
          <td width="125" valign="top" align="left"><a href="#dis"><font face="Verdana, Arial, Helvetica" size="1">Discussion</font></a></td>
        </tr>
        <tr> 
          <td width="10" valign="baseline" align="left"> <font size="1" face="Verdana, Arial, Helvetica" color="#000099">&#149;</font></td>
          <td width="125" valign="top" align="left"><a href="#ref"><font face="Verdana, Arial, Helvetica" size="1">References</font></a></td>
        </tr>
        <tr> 
          <td width="10" valign="baseline" align="left"> <font size="1" face="Verdana, Arial, Helvetica" color="#000099">&#149;</font></td>
          <td width="125" valign="top" align="left"><a href="#table1"><font face="Verdana, Arial, Helvetica" size="1">Table 
            1 </font></a></td>
        </tr>
        <tr> 
          <td width="10" valign="baseline" align="left"> <font size="1" face="Verdana, Arial, Helvetica" color="#000099">&#149;</font></td>
          <td width="125" valign="top" align="left"><a href="#table2"><font face="Verdana, Arial, Helvetica" size="1">Table 
            2 </font></a></td>
        </tr>
        <tr> 
          <td width="10" valign="baseline" align="left"> <font size="1" face="Verdana, Arial, Helvetica" color="#000099">&#149;</font></td>
          <td width="125" valign="top" align="left"><a href="#table3"><font face="Verdana, Arial, Helvetica" size="1">Table 
            3 </font></a></td>
        </tr>
        <tr> 
          <td width="10" valign="baseline" align="left"> <font size="1" face="Verdana, Arial, Helvetica" color="#000099">&#149;</font></td>
          <td width="125" valign="top" align="left"><a href="#table4"><font face="Verdana, Arial, Helvetica" size="1">Table 
            4 </font></a></td>
        </tr>
      </table>
      <!-- #EndEditable --></td>
    <td width="12"><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%" valign="top"><!-- #BeginEditable "content_area_2" --> 
      <p><b><i>Research</i></b></p>
      <h3><font face="Arial, Helvetica, sans-serif">Antimicrobial Susceptibility 
        Breakpoints and First-Step <i>parC</i> Mutations in<i> Streptococcus pneumoniae</i>: 
        Redefining Fluoroquinolone Resistance</font></h3>
      <p><b>Sue Lim,*† Darrin Bast,*† Allison McGeer,*† Joyce de Azavedo,*† and 
        Donald E. Low*†</b><br>
        *Toronto Medical Laboratories/Mount Sinai Hospital, Toronto, Ontario, 
        Canada; and †University of Toronto, Toronto, Ontario, Canada</p>
      <blockquote> 
        <p><font size="2"><i>Suggested citation for this article: </i>Lim S, Bast 
          D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints 
          and first-step <i>parC</i> mutations in <i>Streptococcus pneumoniae</i>: 
          redefining fluoroquinolone resistance. Emerg Infect Dis [serial online] 
          2003 Jul [<i>date cited</i>]. Available from: URL: http://www.cdc.gov/ncidod/EID/vol9no7/02-0589.htm 
          </font><font face="Verdana, Arial, Helvetica" size="1"><b></b></font></p>
      </blockquote>
      <hr>
      <blockquote> 
        <p><font face="Arial, Helvetica, sans-serif" size="2">Clinical antimicrobial 
          susceptibility breakpoints are used to predict the clinical outcome 
          of antimicrobial treatment. In contrast, microbiologic breakpoints are 
          used to identify isolates that may be categorized as susceptible when 
          applying clinical breakpoints but harbor resistance mechanisms that 
          result in their reduced susceptibility to the agent being tested. Currently, 
          the National Committee for Clinical Laboratory Standards (NCCLS) guidelines 
          utilize clinical breakpoints to characterize the activity of the fluoroquinolones 
          against <i>Streptococcus pneumoniae</i>. To determine whether levofloxacin 
          breakpoints can identify isolates that harbor recognized resistance 
          mechanisms, we examined 115 <i>S. pneumoniae</i> isolates with a levofloxacin 
          MIC of <u>&gt;</u>2 &micro;g/mL for first-step <i>parC</i> mutations. 
          A total of 48 (59%) of 82 isolates with a levofloxacin MIC of 2 &micro;g/mL, 
          a level considered susceptible by NCCLS criteria, had a first-step mutation 
          in <i>parC</i>. Whether surveillance programs that use levofloxacin 
          data can effectively detect emerging resistance and whether fluoroquinolones 
          can effectively treat infections caused by such isolates should be evaluated.</font></p>
      </blockquote>
      <p>The emergence of <i>Streptococcus pneumoniae</i> resistance to &szlig;-lactam 
        and macrolide antimicrobial agents has led to recommendations that fluoroquinolones 
        with increased activity against <i>S. pneumoniae</i>, such as levofloxacin, 
        moxifloxacin, and gatifloxacin, be used to treat patients at risk for 
        infection caused by such multidrug-resistant strains (<a href="#1">1-6</a>). 
        Fluoroquinolone resistance in <i>S. pneumoniae</i> is primarily due to 
        mutations in the genes encoding the target topoisomerase enzymes, namely 
        <i>parC</i>, which encodes the A subunit of DNA topoisomerase IV, and 
        <i>gyrA</i>, which encodes the A subunit of DNA gyrase (<a href="#1">7</a>). 
        Mutations in <i>parE</i> and <i>gyrB</i> have been reported, but to a 
        lesser extent (<a href="#1">8-10</a>). Most pneumococcal isolates with 
        reduced susceptibilities to fluoroquinolones have amino acid substitutions 
        in either ParC alone or ParC and GyrA (<a href="#11">11-14</a>). Resistance 
        can also be mediated by active efflux (<a href="#11">15</a>), although 
        the role of efflux in contributing to resistance by the newer fluoroquinolones 
        is unclear (<a href="#11">16</a>).</p>
      <p>The MIC of an antimicrobial agent is a value that has been used to determine 
        breakpoints that predict the probability of clinical success, detect resistant 
        populations, or both (<a href="#11">17</a>). Clinical breakpoints are 
        dependent on the antimicrobial activity and pharmacology of the drug; 
        such breakpoints are ascertained with the goals of eradicating the infection 
        and ultimately achieving clinical success with the antimicrobial agent. 
        In contrast, microbiologic breakpoints are established to identify isolates 
        that may be categorized as susceptible when applying clinical breakpoints 
        but harbor resistance mechanisms that result in their reduced susceptibility 
        to the agent being tested. These microbiologic breakpoints are therefore 
        useful in monitoring the emergence of resistance. The current National 
        Committee for Clinical Laboratory Standards (NCCLS) guidelines make no 
        distinction between these two interpretations of MIC, with clinical breakpoints 
        used to characterize most antimicrobial agents, including the fluoroquinolones.</p>
      <p>Levofloxacin has been used as a surrogate marker to predict fluoroquinolone 
        susceptibility in clinical laboratories and surveillance studies (<a href="#11">18</a>). 
        To establish whether current levofloxacin breakpoints are also able to 
        function as microbiologic breakpoints, we determined the percentage of 
        <i>S. pneumoniae</i> isolates with first-step <i>parC</i> mutations that 
        would go undetected by using the current NCCLS breakpoints for levofloxacin 
        (<a href="#11">19</a>). </p>
      <h3><font face="Arial, Helvetica, sans-serif"><a name="met"></a>Materials 
        and Methods</font></h3>
      <p>A total of 6,076 clinical isolates of <i>S. pneumoniae</i> were collected 
        as part of a 1993-1998 surveillance program throughout Canada. All isolates 
        were identified as <i>S. pneumoniae</i> by standard methods. The isolates 
        were frozen at -70&deg;C, thawed, subcultured onto blood agar, and incubated 
        at 37&deg;C in 5% CO2 for 24 h twice before testing. In vitro susceptibility 
        testing was performed by broth microdilution, according to NCCLS guidelines 
        (<a href="#11">20</a>,<a href="#21">21</a>). Susceptibility interpretive 
        criteria used were those published in the NCCLS M100-S12 document (<a href="#11">19</a>). 
        The nonsusceptible category was defined as those isolates with MICs of 
        fluoroquinolines in the intermediate and resistant category. The <i>parC</i> 
        gene of 115 isolates with a levofloxacin MIC <u>&gt;</u>2 &micro;g/mL 
        (82 = MIC 2 &micro;g/mL; 8 = MIC 4 &micro;g/mL; 10 = MIC 8 &micro;g/mL; 
        and 15 = MIC <u>&gt;</u>16 &micro;g/mL) was amplified by polymerase chain 
        reaction (PCR),  and the nucleotide sequence determined as previously 
        described (<a href="#1">9</a>). All isolates (n=33) with a levofloxacin 
        MIC of <u>&gt;</u>4 &micro;g/mL, and a random sample of 29 isolates with 
        a levofloxacin MIC of 2 &micro;g/mL were examined for <i>gyrA </i>mutations. 
        For comparative purposes, the <i>parC </i>gene of 14 isolates with a ciprofloxacin 
        MIC of 2 &micro;g/mL, regardless of their levofloxacin MIC, was amplified 
        and sequenced. Although numerous single mutational events occur in <i>parC</i>, 
        the focus of this investigation was on amino acid substitutions for Ser-79 
        or Asp-83, because previous studies have consistently demonstrated that 
        mutations at either of these positions are associated with decreased susceptibility 
        (<a href="#1">9</a>,<a href="#11">14</a>).</p>
      <p>Crude cell lysates were used as DNA templates for PCR. After overnight 
        growth on Columbia nutrient agar and supplemented with 5% sheep blood, 
        a loopful of growth was suspended in 100 mL of lysis buffer (100 mM NaCl, 
        10 mM Tris-HCl [pH 8.3], 1 mM EDTA, 1% Triton X-100) and boiled for 10 
        min. Ten microliters of the supernatant was used as the template in a 
        50-mL reaction volume. The quinolone-resistance–determining regions of 
        <i>parC</i> and <i>gyrA</i> were amplified by PCR. Primers used were based 
        on published sequences (<a href="#1">7,8</a>), and amplification products 
        were purified with either the QIAquick PCR purification kit (Qiagen Inc., 
        Mississauga, Ontario, Canada) or the Concert Rapid PCR purification kit 
        (Life Technologies, Burlington, Ontario, Canada).</p>
      <p>DNA sequencing was performed by ABI prism Big Dye terminator cycle sequencing 
        with the ABI 377 automated sequencer (PE Applied Biosystems, Mississauga, 
        Ontario, Canada). Nucleotide and amino acid sequence comparisons were 
        performed by the multiple-alignment sequence function of Vector NTI Suite 
        software (InforMax Inc., Bethesda, MD). The GenBank accession numbers 
        for the wild-type sequences used for comparison purposes were Z67739 for 
        <i>parC</i> and <i>parE </i>(<a href="#21">22</a>), AB010387 for <i>gyrA</i>, 
        and Z67740 for <i>gyrB </i>(<a href="#21">23</a>).</p>
      <p>Isolates were examined for active efflux by agar dilution on Mueller-Hinton 
        agar containing 5% sheep blood in the presence of ciprofloxacin with or 
        without 10 mg/mL of reserpine (Sigma Chemical Co., St. Louis, MO) (<a href="#21">24</a>). 
        Strains for which a fourfold or greater decrease in the MIC of ciprofloxacin 
        existed in the presence of reserpine were considered in this study to 
        be positive for reserpine-inhibited efflux. <i>S. pneumoniae</i> strain 
        P121/1N27 and clinical isolate BSP 823 were used as quality control strains, 
        the latter of which demonstrated a 16-fold decrease in the ciprofloxacin 
        MIC in the presence of reserpine (<a href="#1">9</a>).</p>
      <h3><font face="Arial, Helvetica, sans-serif"><a name="res"></a>Results</font></h3>
      <p>Of the 115 <i>S. pneumoniae</i> isolates with a levofloxacin MIC <u>&gt;</u>2 
        &micro;g/mL, 78 (69%) had an amino acid substitution in ParC (Ser-79 or 
        Asp-83) (<a href="#table1">Table 1</a>). Mutations in <i>gyrA </i>were 
        not found in any of the randomly selected isolates with a levofloxacin 
        MIC of 2 &micro;g/mL, but were present in three (38%) of eight isolates 
        with a levofloxacin MIC of 4 &micro;g/mL and in all isolates with a levofloxacin 
        MIC <u>&gt;</u>8 &micro;g/mL (<a href="#table2">Table 2</a>). The specific 
        ParC amino acid substitutions of the isolates and their corresponding 
        levofloxacin MICs are shown in <a href="#table1">Table 1</a>. The most 
        common substitution was Ser-79 to Phe, accounting for 60% of all observed 
        amino acid substitutions. The prevalence of first-step ParC amino acid 
        substitutions among all strains according to their levofloxacin and ciprofloxacin 
        MICs is shown in <a href="#table3">Table 3</a>. Using the current MIC 
        interpretive standards for levofloxacin, 48 (59%) of 82 of isolates with 
        a first-step mutation fall in the susceptibility category of levofloxacin 
        (MIC&lt;4 &micro;g/mL). In comparison, 4 (29%) of 14 randomly chosen isolates 
        with a ciprofloxacin MIC of 2 &micro;g/mL harbored a first-step mutation.</p>
      <p>Thirty-three isolates were nonsusceptible to levofloxacin (MIC<u>&gt;</u>4 
        &micro;g/mL); for 25, which harbored both ParC and GyrA amino acid substitutions, 
        the levofloxacin MIC was <u>&gt;</u>8 &micro;g/mL (<a href="#table3">Table 
        3</a>). For eight isolates, the levofloxacin MIC was 4 &#956;g/mL; three 
        (38%) of those isolates had a substitution in GyrA (Ser-81-Phe) as well 
        as a substitution in ParC (Ser-79-Phe, Asp-78-Asn and Ala-115-Pro) (<a href="#table4">Table 
        4</a>). In addition, two of the eight (25%) isolates had no substitution 
        in GyrA, but were considered positive for reserpine-inhibited efflux, 
        while three isolates had a Ser-79-Phe amino acid substitution in ParC. 
        No mutations were found in either <i>parE</i> or <i>gyrB</i> in the isolates 
        with a levofloxacin MIC of 4 &micro;g/mL.</p>
      <h3><font face="Arial, Helvetica, sans-serif"><a name="dis"></a>Discussion</font> 
      </h3>
      <p>Before the development of fluoroquinolones such as levofloxacin, ofloxacin 
        was used to determine trends of pneumococcal fluoroquinolone resistance 
        in the United States (<a href="#21">25</a>). By using this system, an 
        increase of ofloxacin-nonsusceptible isolates from 2.6% in 1995 to 3.8% 
        in 1997 was reported. However, the significance of such an increase was 
        questioned, since ofloxacin-resistant strains could be observed with only 
        a single topoisomerase mutation, whereas for fluoroquinolones such as 
        levofloxacin, multiple mutations are required for a strain to be classified 
        as resistant according to NCCLS breakpoints (<a href="#21">25-27</a>). 
        As a consequence, ofloxacin was replaced by levofloxacin in 1998 as a 
        marker for fluoroquinolone nonsusceptibility, and not surprisingly, given 
        levofloxacin’s increased activity against <i>S. pneumoniae</i>, fluoroquinolone 
        resistance rates were only 0.2% in 1998 and 1999 (<a href="#21">25</a>). 
      </p>
      <p>Since effective surveillance depends upon the ability to detect the emergence 
        of resistance, the prevalence of pneumococci that harbor resistance mechanisms 
        to the fluoroquinolones may not be accurately represented if surveillance 
        systems that rely on levofloxacin MIC data are used (<a href="#21">25,28-34</a>). 
        We found that 59% of isolates with a levofloxacin MIC of 2 &micro;g/mL, 
        a level considered susceptible according to NCCLS criteria, had a first-step 
        mutation in <i>parC</i>. Similarly, Davies et al. (<a href="#11">12</a>) 
        found that of 14 strains for which levofloxacin MICs were 2 &micro;g/mL, 
        10 (71%) had a <i>parC</i> mutation. Therefore, if the goal of surveillance 
        is to detect emerging problems, then by extension, the detection of first-step 
        mutations is also important and the use of current NCCLS breakpoints to 
        estimate fluoroquinolone resistance is clearly inadequate. Apart from 
        DNA sequencing, currently no accurate test can reliably identify isolates 
        with first-step mutations (<a href="#31">35</a>). Although decreasing 
        levofloxacin breakpoints has been proposed as a solution to this problem, 
        we found that 8 (25%) of 32 strains for which the levofloxacin MIC was 
        1 &micro;g/mL already had first-step mutations (data not shown). Similarly, 
        the replacement of levofloxacin as a surveillance indicator by another 
        fluoroquinolone has also been suggested. However, use of ciprofloxacin 
        does not fare significantly better, with 4 (29%) of 14 isolates in the 
        susceptible category (MIC of 4 &micro;g/mL to define nonsusceptible isolates) 
        harboring first-step mutations.</p>
      <p>In addition to causing an underestimation of the emergence of fluoroquinolone 
        resistance, the use of clinical breakpoints has therapeutic implications, 
        as supported by recent reports of treatment failure when a fluoroquinolone 
        was used to treat an infection caused by a strain of pneumococci with 
        a first-step mutation (<a href="#31">36,37</a>). Clearly, a first-step 
        mutation is necessary for the development of subsequent mutations, the 
        latter of which result in MICs that fall within the nonsusceptible category. 
        However, studies have shown that upon acquisition of a first-step mutation, 
        the likelihood of developing a subsequent mutation is enhanced in comparison 
        to the development of the first-step mutation itself (<a href="#31">38-40</a>). 
        Studies are required to determine whether isolates with one or more mutations 
        in genes encoding ParC, GyrA, or both, can still be effectively treated 
        with a fluoroquinolone when that fluoroquinolone is found to be susceptible 
        by using current clinical breakpoints. Recognizing the presence of underlying 
        mutations may be especially important when using these agents to treat 
        patients with large biomass infections such as pneumococcal pneumonia.</p>
      <p>Lastly, the acquisition of a second-step mutation appears more likely 
        than not to raise the MIC to <u>&gt;</u>8 &micro;g/mL and not to 4 &micro;g/mL 
        as would be expected. Isolates with a levofloxacin MIC of 4 &micro;g/mL 
        represented 0.1% of the total number of isolates in our study, which is 
        notable, considering that a levofloxacin MIC of 4 &micro;g/mL is currently 
        used to define nonsusceptibility. Furthermore, these isolates were for 
        the most part either genotypically or phenotypically distinct from other 
        isolates characterized (<a href="#table4">Table 4</a>); two had efflux 
        mechanisms, one singly and the other concurrent with a ParC amino acid 
        substitution, and two had unusual substitutions in ParC (Asp78<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Asn 
        and Ala115<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Pro). 
        The importance of this latter finding remains to be determined.</p>
      <p>In summary, levofloxacin susceptibility testing that uses current MIC 
        clinical breakpoints does not identify most <i>S. pneumoniae</i> isolates 
        with only first-step <i>parC</i> mutations. This finding may not only 
        have implications for the ability of surveillance programs to detect emerging 
        resistance, but therapeutic implications as well.</p>
      <blockquote> 
        <p><font size="2" face="Arial, Helvetica, sans-serif">Dr. Lim is a physician 
          trained in internal medicine and currently a fellow in infectious diseases 
          and medical microbiology at the University of Toronto. Her research 
          interests include infections in the immunocrompromised host and transplant 
          recipients.</font></p>
        <p><font size="2" face="Arial, Helvetica, sans-serif">This work was supported 
          by grants from Hoffman-La Roche and the Canadian Bacterial Diseases 
          Network.</font></p>
      </blockquote>
      <h4><font face="Arial, Helvetica, sans-serif"><a name="ref"></a>References</font></h4>
      <ol>
        <li><a name="1"></a>Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher 
          DM, Fine A. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10987697&dopt=Abstract" target="_blank">Practice 
          guidelines for the management of community-acquired pneumonia in adults.</a> 
          Clin Infect Dis 2000;31:347–82.</li>
        <li>Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell 
          GD, et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11401897&dopt=Abstract" target="_blank">Guidelines 
          for the management of adults with community-acquired pneumonia. Diagnosis, 
          assessment of severity, antimicrobial therapy, and prevention.</a> Am 
          J Respir Crit Care Med 2001;163:1730–54.</li>
        <li>Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10987698&dopt=Abstract" target="_blank">Canadian 
          guidelines for the initial management of community-acquired pneumonia: 
          an evidence-based update by the Canadian Infectious Diseases Society 
          and the Canadian Thoracic Society.</a> Clin Infect Dis 2000;31:383–421.</li>
        <li>Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher 
          DM, et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10826451&dopt=Abstract" target="_blank">Management 
          of community-acquired pneumonia in the era of pneumococcal resistance: 
          a report from the Drug-Resistant <i>Streptococcus pneumoniae</i> Therapeutic 
          Working Group.</a> Arch Intern Med 2000;160:1399–408.</li>
        <li>File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, 
          et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9303395&dopt=Abstract" target="_blank">A 
          multicenter, randomized study comparing the efficacy and safety of intravenous 
          and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil 
          in treatment of adults with community-acquired pneumonia.</a> Antimicrob 
          Agents Chemother 1997;41:1965–72.</li>
        <li>Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11157603&dopt=Abstract" target="_blank">Oral 
          moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, 
          community-acquired, suspected pneumococcal pneumonia in adults.</a> 
          Chest 2001;119:185–95.</li>
        <li>Pan XS, Ambler J, Mehtar S, Fisher LM. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8891138&dopt=Abstract" target="_blank">Involvement 
          of topoisomerase IV and DNA gyrase as ciprofloxacin targets in <i>Streptococcus 
          pneumoniae</i>.</a> Antimicrob Agents Chemother 1996;40:2321–6.</li>
        <li>Perichon B, Tankovic J, Courvalin P. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9145891&dopt=Abstract" target="_blank">Characterization 
          of a mutation in the parE gene that confers fluoroquinolone resistance 
          in <i>Streptococcus pneumoniae</i>.</a> Antimicrob Agents Chemother 
          1997;41:1166–7.</li>
        <li>Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, et 
          al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11036021&dopt=Abstract" target="_blank">Fluoroquinolone 
          resistance in clinical isolates of <i>Streptococcus pneumoniae</i>: 
          contributions of type II topoisomerase mutations and efflux to levels 
          of resistance.</a> Antimicrob Agents Chemother 2000;44:3049–54.</li>
        <li>Weigel LM, Anderson GJ, Facklam RR, Tenover FC. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11709333&dopt=Abstract" target="_blank">Genetic 
          analyses of mutations contributing to fluoroquinolone resistance in 
          clinical isolates of <i>Streptococcus pneumoniae</i>.</a> Antimicrob 
          Agents Chemother 2001;45:3517–23.</li>
        <li><a name="11"></a>Ho PL, Yam WC, Que TL, Tsang DN, Seto WH, Ng TK, 
          et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11328779&dopt=Abstract" target="_blank">Target 
          site modifications and efflux phenotype in clinical isolates of <i>Streptococcus 
          pneumoniae</i> from Hong Kong with reduced susceptibility to fluoroquinolones.</a> 
          J Antimicrob Chemother. 2001;47:655–8.</li>
        <li>Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt 
          R. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11751121&dopt=Abstract" target="_blank">Prevalence 
          of single mutations in topoisomerase type II genes among levofloxacin-susceptible 
          clinical strains of <i>Streptococcus pneumoniae</i> isolated in the 
          United States in 1992 to 1996 and 1999 to 2000.</a> Antimicrob Agents 
          Chemother 2002;46:119–24.</li>
        <li>Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, 
          et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10639387&dopt=Abstract" target="_blank">Prevalence 
          of <i>gyrA</i>, <i>gyrB</i>, <i>parC</i>, and <i>parE </i>mutations 
          in clinical isolates of <i>Streptococcus pneumoniae</i> with decreased 
          susceptibilities to different fluoroquinolones and originating from 
          worldwide surveillance studies during the 1997–1998 respiratory season.</a> 
          Antimicrob Agents Chemother 2000;44:462–6.</li>
        <li>Brueggemann AB, Coffman SL, Rhomberg P, Huynh H, Almer L, Nilius A, 
          et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11850248&dopt=Abstract" target="_blank">Fluoroquinolone 
          resistance in <i>Streptococcus pneumoniae </i>in United States since 
          1994–1995.</a> Antimicrob Agents Chemother 2002;46:680–8.</li>
        <li>Gill MJ, Brenwald NP, Wise R. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9869592&dopt=Abstract" target="_blank">Identification 
          of an efflux pump gene, <i>pmrA</i>, associated with fluoroquinolone 
          resistance in <i>Streptococcus pneumoniae</i>.</a> Antimicrob Agents 
          Chemother 1999;43:187–9.</li>
        <li>Piddock LJ, Johnson MM, Simjee S, Pumbwe L. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11850265&dopt=Abstract" target="_blank">Expression 
          of efflux pump gene <i>pmrA</i> in fluoroquinolone-resistant and -susceptible 
          clinical isolates of <i>Streptococcus pneumoniae</i>.</a> Antimicrob 
          Agents Chemother 2002;46:808–12.</li>
        <li>Mouton JW. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11978503&dopt=Abstract" target="_blank">Breakpoints: 
          current practice and future perspectives.</a> Int J Antimicrob Agents 
          2002;19:323–31.</li>
        <li>Jones RN, Pfaller MA. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11404067&dopt=Abstract" target="_blank">Can 
          antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin 
          predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report 
          from the SENTRY Antimicrobial Surveillance Program (1997–99).</a> Diagn 
          Microbiol Infect Dis 2001;39:237–43.</li>
        <li>National Committee for Clinical Laboratory Standards. Performance 
          standards for antimicrobial susceptibility testing. Twelfth informational 
          supplement, M100-S12. Wayne (PA): The Committee; 2002.</li>
        <li>National Committee for Clinical Laboratory Standards. Methods for 
          dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 
          5th ed. Approved standard M7-A5. Wayne (PA): The Committee; 2000.</li>
        <li><a name="21"></a>National Committee for Clinical Laboratory Standards. 
          Performance standards for antimicrobial disk susceptibility tests, 7th 
          ed. Approved standard M2-A7. 7th ed. Wayne (PA): The Committee; 2000.</li>
        <li>Pan XS, Fisher LM. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8763932&dopt=Abstract" target="_blank">Cloning 
          and characterization of the <i>parC</i> and <i>parE</i> genes of <i>Streptococcus 
          pneumoniae</i> encoding DNA topoisomerase IV: role in fluoroquinolone 
          resistance.</a> J Bacteriol 1996:178;4060–9.</li>
        <li>Munoz R, Bustamante M, De La Campa AG. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7608096&dopt=Abstract" target="_blank">Ser-127-to-Leu 
          substitution in the DNA gyrase B subunit of <i>Streptococcus pneumoniae</i> 
          is implicated in novobiocin resistance.</a> J Bacteriol 1995:177;4166–70.</li>
        <li>Brenwald NP, Gill MJ, Wise R. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9687402&dopt=Abstract" target="_blank">Prevalence 
          of a putative efflux mechanism among fluoroquinolone-resistant clinical 
          isolates of <i>Streptococcus pneumoniae</i>.</a> Antimicrob Agents Chemother 
          1998;42:2032–5.</li>
        <li>Centers for Disease Control. Resistance of <i>Streptococcus pneumoniae 
          </i>to fluoroquinolones—United States, 1995–1999. MMWR Morb Mortal Wkly 
          Rep 2001;50:800–4.</li>
        <li>Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9925527&dopt=Abstract" target="_blank">Activities 
          of newer fluoroquinolones against <i>Streptococcus pneumoniae</i> clinical 
          isolates including those with mutations in the <i>gyrA</i>, <i>parC</i>, 
          and <i>parE</i> loci.</a> Antimicrob Agents Chemother 1999;43:329–34.</li>
        <li>Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro MJ, Tenover 
          FC. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11036007&dopt=Abstract" target="_blank">Activities 
          of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against 
          recent clinical isolates of levofloxacin- resistant <i>Streptococcus 
          pneumoniae</i>.</a> Antimicrob Agents Chemother 2000;44:2962–8.</li>
        <li>Ho PL, Yung RW, Tsang DN, Que TL, Ho M, Seto WH, et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11679555&dopt=Abstract" target="_blank">Increasing 
          resistance of <i>Streptococcus pneumoniae</i> to fluoroquinolones: results 
          of a Hong Kong multicentre study in 2000.</a> J Antimicrob Chemother 
          2001;48:659–65.</li>
        <li>Jones ME, Karlowsky JA, Blosser-Middleton R, Critchley IA, Karginova 
          E, Thornsberry C, et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12121949&dopt=Abstract" target="_blank">Longitudinal 
          assessment of antipneumococcal susceptibility in the United States.</a> 
          Antimicrob Agents Chemother 2002;46:2651–5.</li>
        <li>McGee L, Klugman KP, Wasas A, Capper T, Brink A. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11302838&dopt=Abstract" target="_blank">Serotype 
          19f multiresistant pneumococcal clone harboring two erythromycin resistance 
          determinants (<i>erm</i>(B) and <i>mef</i>(A)) in South Africa.</a> 
          Antimicrob Agents Chemother 2001;45:1595–8.</li>
        <li><a name="31"></a>Critchley IA, Blosser RS, Karlowsky JA, Yamakita 
          J, Barth A, Sader HS, et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11980591&dopt=Abstract" target="_blank">Antimicrobial 
          resistance in respiratory pathogens isolated in Brazil during 1999–2000.</a> 
          Braz J Infect Dis 2001;5:294–304.</li>
        <li>Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10590275&dopt=Abstract">Resistance 
          surveillance of <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae 
          </i>and <i>Moraxella catarrhalis</i> isolated in the United States, 
          1997–1998.</a> J Antimicrob Chemother 1999;44:749–59.</li>
        <li>Schmitz FJ, Perdikouli M, Beeck A, Verhoef J, Fluit AC. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11711257&dopt=Abstract" target="_blank">Molecular 
          surveillance of macrolide, tetracycline and quinolone resistance mechanisms 
          in 1191 clinical European <i>Streptococcus pneumoniae </i>isolates.</a> 
          Int J Antimicrob Agents 2001;18:433–6.</li>
        <li>Reinert RR, Simic S, Al Lahham A, Reinert S, Lemperle M, Lutticken 
          R. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11230456&dopt=Abstract" target="_blank">Antimicrobial 
          resistance of <i>Streptococcus pneumoniae</i> recovered from outpatients 
          with respiratory tract infections in Germany from 1998 to 1999: results 
          of a national surveillance study.</a> J Clin Microbiol 2001;39:1187–9.</li>
        <li>Richardson DC, Bast D, McGeer A, Low DE. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11353652&dopt=Abstract" target="_blank">Evaluation 
          of susceptibility testing to detect fluoroquinolone resistance mechanisms 
          in <i>Streptococcus pneumoniae</i>.</a> Antimicrob Agents Chemother 
          2001;45:1911–4.</li>
        <li>Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey 
          P, et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11882730&dopt=Abstract" target="_blank">Resistance 
          to levofloxacin and failure of treatment of pneumococcal pneumonia.</a> 
          N Engl J Med 2002;346:747–50.</li>
        <li>Weiss K, Restieri C, Gauthier R, Laverdiere M, McGeer A, Davidson 
          RJ, et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11462189&dopt=Abstract" target="_blank">A 
          nosocomial outbreak of fluoroquinolone-resistant <i>Streptococcus pneumoniae</i>.</a> 
          Clin Infect Dis 2001;33:517–22.</li>
        <li>Pestova E, Millichap JJ, Noskin GA, Peterson LR. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10797078&dopt=Abstract" target="_blank">Intracellular 
          targets of moxifloxacin: a comparison with other fluoroquinolones.</a> 
          J Antimicrob Chemother 2000;45:583–90.</li>
        <li>Li X, Zhao X, Drlica K. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11796368&dopt=Abstract" target="_blank">Selection 
          of <i>Streptococcus pneumoniae </i>mutants having reduced susceptibility 
          to moxifloxacin and levofloxacin.</a> Antimicrob Agents Chemother 2002;46:522–4.</li>
        <li>Gillespie SH, Dickens A. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12705679&dopt=Abstract" target="_blank">Fluoroquinolone 
          resistance in <i>Streptococcus pneumoniae:</i> evidence that <i>gyrA</i> 
          mutations arise at a lower rate and that mutation in <i>gyrA</i> or 
          <i>parC </i>predisposes to further mutation.</a> Microb Drug Resist 
          2003;9:17–24.</li>
      </ol>
      <p>&nbsp;</p>
      <table border=0 cellspacing=0 cellpadding=0 width="100%">
        <tr> 
          <td colspan="7" valign=top> 
            <p><font size="2"><b><a name="table1"></a>Table 1.</b> ParC amino 
              acid substitutions found in 115 <i>Streptococcus pneumoniae</i> 
              isolates with levofloxacin MICs <u>&gt;</u>2 &micro;g/mL and corresponding 
              levofloxacin MICs</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="7"> 
            <hr size="1" noshade>
          </td>
        </tr>
        <tr> 
          <td rowspan="3" valign="bottom" width="36%"> 
            <p><font size="2">ParC amino acid substitution</font></p>
          </td>
          <td colspan=5 valign="bottom"> 
            <p align=center><font size="2">No. isolates inhibited by levofloxacin 
              MIC (µg/mL) of</font></p>
          </td>
          <td rowspan="3" valign="bottom" width="30%"> 
            <p align=center><font size="2">Total no.<br>
              of strains</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="5"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign="bottom" width="7%"> 
            <p align=center><font size="2">2</font></p>
          </td>
          <td valign="bottom" width="6%"> 
            <p align=center><font size="2">4</font></p>
          </td>
          <td valign="bottom" width="7%"> 
            <p align=center><font size="2">8</font></p>
          </td>
          <td valign="bottom" width="7%"> 
            <p align=center><font size="2">16</font></p>
          </td>
          <td valign="bottom" width="7%"> 
            <p align=center><font size="2"><u>&gt;</u>32</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="7"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">Ser79<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">28</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">4</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">3</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">9</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">3</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">47</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">Ser79<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Tyr</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">7</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">1</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">3</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">2</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">1</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">14</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">Ser79<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Ala</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">1</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">1</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">Asp83<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Asn</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">7</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">3</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">10</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">Asp83<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Gly</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">1</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">1</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">Asp83<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Tyr</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">3</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">3</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">Asp83<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Val</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">1</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">1</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">Asp83<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Ala</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">1</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">0</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">1</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top width="36%"> 
            <p><font size="2">No. isolates/total with amino acid substitutions</font></p>
          </td>
          <td valign=bottom width="7%"> 
            <p align=center><font size="2">48/82<br>
              (59%)</font></p>
          </td>
          <td valign=top width="6%"> 
            <p align=center><font size="2">5/8<sup>a</sup> <br>
              (63%)</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">10/10</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">11/11</font></p>
          </td>
          <td valign=top width="7%"> 
            <p align=center><font size="2">4/4</font></p>
          </td>
          <td valign=top width="30%"> 
            <p align=center><font size="2">78/115 <br>
              (69%)</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="7"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign=top colspan="7"><font size="2"><sup>a</sup>One isolate with 
            no ParC amino acid substitution found to have active efflux; two isolates 
            had ParC amino acid substitutions at sites other than Ser79 or Asp83.</font></td>
        </tr>
      </table>
      <p>&nbsp;</p>
      <table border=0 cellspacing=0 cellpadding=0 width="100%">
        <tr> 
          <td colspan="3" valign=bottom> 
            <p><font size="2"><b><a name="table2"></a>Table 2.</b> Number of isolates 
              with ParC and GyrA amino acid substitutions and their corresponding 
              levofloxacin MICs</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="3"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td rowspan=3 valign=bottom> 
            <p><font size="2">MIC<br>
              (&micro;g/mL)</font></p>
          </td>
          <td valign=bottom colspan=2> 
            <p align=center><font size="2">No.  strains with amino acid substitutions 
              in</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="2"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td> 
            <p align=center><font size="2">ParC (%)</font></p>
          </td>
          <td> 
            <p align=center><font size="2">ParC and GyrA (%)</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="3"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2">2</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">48/82 (59)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">0/29<sup>a</sup> (0)</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2">4</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">5/8 (63)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">3/8 (38)</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2">8</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">0/10 (0)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">10/10 (100)</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2"><u>&gt;</u>16</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">0/15 (0)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">15/15 (100)</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="3"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign=top colspan="3"><sup><font size="2">a</font></sup><font size="2">29/82 
            isolates were randomly examined for GyrA mutations.</font></td>
        </tr>
      </table>
      <p>&nbsp;</p>
      <table border=0 cellspacing=0 cellpadding=0 width="100%">
        <tr> 
          <td valign=bottom colspan="3"> 
            <p><font size="2"><b><a name="table3"></a>Table 3.</b> The prevalence 
              of ParC amino acid substitutions among all strains according to 
              their levofloxacin and ciprofloxacin MICs</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="3"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td rowspan=3 valign=bottom> 
            <p><font size="2">MIC (&micro;g/mL)</font></p>
          </td>
          <td colspan=2 valign=top> 
            <p align=center><font size="2">No. strains with ParC amino acid substitution 
              at 79 or 83</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="2"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p align=center><font size="2">Ciprofloxacin (%)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">Levofloxacin (%)</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="3"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2">2</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">4/14 (29)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">48/82 (59)</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2">4</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">24/37 (65)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">5/8 (63)</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2">8</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">11/12 (92)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">10/10 (100)</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2">&gt;8</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">22/22 (100)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">15/15 (100)</font></p>
          </td>
        </tr>
        <tr> 
          <td valign=top> 
            <p><font size="2">Total</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">62/87 (71)</font></p>
          </td>
          <td valign=top> 
            <p align=center><font size="2">78/115 (69)</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="3"> 
            <hr noshade size="1">
          </td>
        </tr>
      </table>
      <p>&nbsp;</p>
      <table border=0 cellspacing=0 cellpadding=0>
        <tr> 
          <td colspan="4" valign=bottom> 
            <p><font size="2"><b><a name="table4"></a>Table 4.</b> Characterization 
              of <i>Streptococcus pneumoniae</i> isolates with levofloxacin MIC 
              4 &micro;g/mL<sup>a</sup></font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="4"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td rowspan=3 valign=bottom> 
            <p><font size="2">Isolate no.</font></p>
          </td>
          <td valign=bottom colspan=2> 
            <p align=center><font size="2">Amino acid substitution</font></p>
          </td>
          <td rowspan=3 valign=bottom> 
            <p align=center><font size="2">Change in MIC with inhibition of efflux</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="2"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign=bottom> 
            <p align=center><font size="2">In ParC</font></p>
          </td>
          <td valign=bottom> 
            <p align=center><font size="2">In GyrA</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="4"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr valign="top"> 
          <td> 
            <p><font size="2">1</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ser79<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td> 
            <p align=center><font size="2">None</font></p>
          </td>
          <td> 
            <p align=center><font size="2">8-fold</font></p>
          </td>
        </tr>
        <tr valign="top"> 
          <td> 
            <p><font size="2">2</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ser79<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td> 
            <p align=center><font size="2">None</font></p>
          </td>
          <td> 
            <p align=center><font size="2">No effect</font></p>
          </td>
        </tr>
        <tr valign="top"> 
          <td> 
            <p><font size="2">3</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Asp78<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Asn</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ser81<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td> 
            <p align=center><font size="2">No effect</font></p>
          </td>
        </tr>
        <tr valign="top"> 
          <td> 
            <p><font size="2">4</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ala115<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Pro</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ser81<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td> 
            <p align=center><font size="2">No effect</font></p>
          </td>
        </tr>
        <tr valign="top"> 
          <td> 
            <p><font size="2">5</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ser79<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td> 
            <p align=center><font size="2">None</font></p>
          </td>
          <td> 
            <p align=center><font size="2">No effect</font></p>
          </td>
        </tr>
        <tr valign="top"> 
          <td> 
            <p><font size="2">6</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ser79<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td> 
            <p align=center><font size="2">None</font></p>
          </td>
          <td> 
            <p align=center><font size="2">No effect</font></p>
          </td>
        </tr>
        <tr valign="top"> 
          <td> 
            <p><font size="2">7</font></p>
          </td>
          <td> 
            <p align=center><font size="2">None</font></p>
          </td>
          <td> 
            <p align=center><font size="2">None</font></p>
          </td>
          <td> 
            <p align=center><font size="2">4-fold</font></p>
          </td>
        </tr>
        <tr valign="top"> 
          <td> 
            <p><font size="2">8</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ser79<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td> 
            <p align=center><font size="2">Ser81<img src="../images/right_arrow.gif" width="15" height="11" alt="right arrow">Phe</font></p>
          </td>
          <td> 
            <p align=center><font size="2">No effect</font></p>
          </td>
        </tr>
        <tr> 
          <td colspan="4"> 
            <hr noshade size="1">
          </td>
        </tr>
        <tr> 
          <td valign=top colspan="4"><font size="2"><sup>a</sup><i>parE </i>and 
            <i>gyrB </i>sequencing was performed on all isolates, but no mutations 
            were found in the quinolone-resistance–determining region.</font></td>
        </tr>
      </table>
      <!-- #EndEditable --> </td>
  </tr>
</table>
<table width="98%" border="0" cellspacing="0" cellpadding="0">
  <tr> 
    <td width="140" bgcolor="#CCCCCC">&nbsp;</td>
    <td width="12">&nbsp;</td>
    <td width="100%"> 
      <hr width="100%">
    </td>
  </tr>
  <tr> 
    <td width="140" bgcolor="#CCCCCC">&nbsp;</td>
    <td width="12">&nbsp;</td>
    <td width="100%">&nbsp;</td>
  </tr>
  <tr> 
    <td width="140" bgcolor="#CCCCCC">&nbsp;</td>
    <td width="12">&nbsp;</td>
    <td width="100%"><!-- #BeginEditable "comments" --> 
      <table border="0" cellpadding="1" cellspacing="0" bgcolor="000088" width="440">
        <tr> 
          <td align="center"> 
            <table border="0" cellspacing="0" cellpadding="5" width="512">
              <tr> 
                <td bgcolor="#000080"><font face="Arial" color="#FFFF00"><strong><a name="com"></a>Comments 
                  to the Authors</strong></font></td>
              </tr>
              <tr> 
                <td bgcolor="#FFFFCc" valign="baseline"> 
                  <p><font face="Arial, Helvetica, sans-serif" size="2">Please 
                    use the form below to submit correspondence to the authors 
                    or contact them at the following address:</font></p>
                  <p><font face="Arial, Helvetica, sans-serif" size="2">Donald 
                    E. Low, Department of Microbiology, Rm. 1487, Mount Sinai 
                    Hospital, 600 University Ave., Toronto, Ontario, Canada, M5G 
                    1X5; fax: 416-586-8746; email: <a href="mailto:dlow@mtsinai.on.ca">dlow@mtsinai.on.ca</a></font></p>
                  <form action="http://www.cdc.gov/cgi-bin/sendit.exe" method="post">
                    <input type="hidden" name="LineWrap" value="2048">
                    <input type="hidden" name="LookBack" value="15">
                    <input type="hidden" name="RCPT" value="dlow@mtsinai.on.ca">
                    <input type="hidden" name="refer" value="ncidod/eid/comment_thx.htm">
                    <input type="hidden" name="SMTP" value="FormMail.cdc.gov">
                    <input type="hidden" name="Subject" value="Your article in the EID Journal">
                    <p> 
                      <textarea rows=" 10" cols="60" 5" comments name="textarea"">Comments:</textarea>
                    </p>
                    <p><font face="Arial" size="2">Return Email address optional:</font><br>
                      <input type="text" name="From" size="35">
                      <br>
                      <br>
                      <input type="submit" value="Submit" name="submit">
                      <input type="reset" value="Reset" name="reset">
                    </p>
                  </form>
                  <p>&nbsp;</p>
                </td>
              </tr>
            </table>
          </td>
        </tr>
      </table>
      <br>
      <!-- #BeginLibraryItem "/Library/comments.lbi" --><table border="0" cellpadding="1" cellspacing="0" bgcolor="000088" width="440">
   <tr>      
    <td align="center"> 
      <table border="0" cellpadding="1" cellspacing="0" bgcolor="000088" width="440">
        <tr> 
          <td align="center"> 
            <table border="0" cellspacing="0" cellpadding="5" width="439">
              <tr> 
                <td bgcolor="#000080"><font face="Arial" color="#FFFF00"><strong>Comments 
                  to the EID Editors</strong></font></td>
              </tr>
              <tr> 
                <td bgcolor="#FFFFCc" valign="baseline"><font face="Arial" size="2">Please 
                  contact the EID Editors at <a href="mailto:eideditor@cdc.gov">eideditor@cdc.gov</a></font></td>
              </tr>
            </table>
          </td>
        </tr>
      </table>
    </td>
   </tr>
  </table><!-- #EndLibraryItem --><br>
      <table border="0" cellpadding="1" cellspacing="0" bgcolor="000088" width="440">
        <tr> 
          <td align="center"> 
            <table border="0" cellspacing="0" cellpadding="5" width="512">
              <tr> 
                <td bgcolor="#000080"><font face="Arial" color="#FFFF00"><strong><a name="email"></a>Email 
                  this article</strong></font></td>
              </tr>
              <tr> 
                <td bgcolor="#FFFFCc" valign="baseline"> 
                  <form action="http://www.cdc.gov/cgi-bin/sendit.exe" method="post">
                    <p><font face="Arial, Helvetica, sans-serif" size="2">Your 
                      email</font>:<br>
                      <input type="text" name="From" size="35">
                    </p>
                    <p><font face="Arial" size="2">Your friend's email</font>:<br>
                      <input type="text" name="RCPT" size="35">
                    </p>
                    <p> 
                      <input type="hidden" name="LineWrap" value="2048">
                      <input type="hidden" name="LookBack" value="15">
                      <input type="hidden" name="refer" value="ncidod/eid/email_thx.htm">
                      <input type="hidden" name="SMTP" value="FormMail.cdc.gov">
                      <input type="hidden" name="Subject" value="Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance">
                    </p>
                    <p><font face="Arial, Helvetica, sans-serif" size="2">Message 
                      (optional):</font><br>
                      <textarea rows=" 10" cols="60" 5" name="Article of interest in Emerging Infectious Diseases Journal"></textarea>
                    </p>
                    <input type="hidden" name="Click link below to view article or copy and paste link into your Web Browser's address window and hit enter." 

value="Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance
http://www.cdc.gov/ncidod/EID/vol9no7/02-0589.htm">
                    <p>&nbsp;</p>
                    <input type="submit" value="Submit" name="">
                    <input type="reset" value="Reset" name="">
                  </form>
                  <p>&nbsp; </p>
                </td>
              </tr>
            </table>
          </td>
        </tr>
      </table>
      <!-- #EndEditable --></td>
  </tr>
  <tr> 
    <td width="140" bgcolor="#CCCCCC"><img src="../images/spacer.gif" width="140" height="1" alt=" "></td>
    <td width="12"><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%"> 
      <p>&nbsp;</p>
    </td>
  </tr>
</table>
<table width="98%" border="0" cellspacing="0" cellpadding="0">
  <tr> 
    <td width="140" bgcolor="#CCCCCC"><img src="../images/spacer.gif" width="140" height="1" alt=" "></td>
    <td width="12"><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%"> 
      <p><!-- #BeginLibraryItem "/Library/footer_1.lbi" --><font face="Verdana, Arial, Helvetica" size="1"><a href="../index.htm"><b>EID 
Home</b></a> <b>| <a href="#top">Top of Page</a> | <a href="../upcoming.htm">Ahead-of-Print</a> 
| <a href="../pastcon.htm">Past Issues</a>&nbsp;</b></font><font face="Verdana, Arial, Helvetica" size="1"><b>| 
<a href="../citation.htm">Suggested Citation</a><a href="#top"></a> | <a href="../upcoming.htm"></a><a href="../search.htm">EID 
Search</a> | <a href="../feedback.htm">Contact Us</a> | <a href="http://www.cdc.gov/accessibility/alt508.html">Accessibility</a> 
| <a href="http://www.cdc.gov/privacy.htm">Privacy Policy Notice</a> | <a href="http://www.cdc.gov/">CDC 
Home</a> | </b><a href="http://www.cdc.gov/search.htm"><b>CDC Search</b></a> <b>| 
<a href="http://www.cdc.gov/health/diseases.htm">Health Topics A-Z</a></b></font><font face="Verdana, Arial, Helvetica" size="1"><b></b></font><!-- #EndLibraryItem --></p>
    </td>
  </tr>
  <tr> 
    <td width="140" bgcolor="#CCCCCC"><img src="../images/spacer.gif" width="1" height="10" alt=" "></td>
    <td width="12"><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%"></td>
  </tr>
</table>
<table width="98%" border="0" cellspacing="0" cellpadding="0">
  <tr> 
    <td width="140" bgcolor="#CCCCCC"><img src="../images/spacer.gif" width="140" height="1" alt=" "></td>
    <td width="12"><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%"> 
      <p><font size="2" face="Verdana, Arial, Helvetica">This page posted <!-- #BeginEditable "date" -->June 
        3, 2003<!-- #EndEditable --><br>
        This page last reviewed <font size="2" face="Verdana, Arial, Helvetica"> 
        <font size="2" face="Verdana, Arial, Helvetica"><font size="2" face="Verdana, Arial, Helvetica"> 
        <!-- #BeginDate format:Am1 -->January 2, 2004<!-- #EndDate -->
        </font></font></font></font></p>
    </td>
  </tr>
  <tr> 
    <td width="140" bgcolor="#CCCCCC"><img src="../images/spacer.gif" width="1" height="10" alt=" "></td>
    <td width="12"><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%"></td>
  </tr>
</table>
<table width="98%" border="0" cellspacing="0" cellpadding="0">
  <tr> 
    <td width="140" bgcolor="#CCCCCC"><img src="../images/spacer.gif" width="140" height="1" alt=" "></td>
    <td width="12"><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%"> 
      <p><!-- #BeginLibraryItem "/Library/footer_2.lbi" --><font face="Verdana, Arial, Helvetica" size="1"><a href="../index.htm"><i>Emerging 
Infectious Diseases</i> Journal</a><br>
<a href="/ncidod/index.htm">National Center for Infectious Diseases</a><br>
<a href="http://www.cdc.gov/">Centers for Disease Control and Prevention</a><br>
<br>
</font><!-- #EndLibraryItem --></p>
    </td>
  </tr>
  <tr> 
    <td width="140" bgcolor="#CCCCCC"><img src="../images/spacer.gif" width="1" height="10" alt=" "></td>
    <td width="12"><img src="../images/spacer.gif" width="12" height="1" alt=" "></td>
    <td width="100%"></td>
  </tr>
</table>
<!-- ####################################  -->
<!-- BEGIN SiteCatalyst/Omniture code here-->
<!-- Version 1.2: Date Created: 08/04/2004-->
<script language="JavaScript" type="text/javascript">
<!--
var s_pageName=document.title
var s_channel="EidNCID"
var s_prop1= s_pageName + " ^ " + s_channel
var s_code=' '//-->
</script>
<script language="JavaScript" src="/JScript/s_code.js" type="text/javascript"></script>
<script language="JavaScript" type="text/javascript">
<!--
var s_wd=window,s_tm=new Date;if(s_code!=' '){s_code=s_dc('cdcgov');if(s_code)document.write(s_code)}else
document.write('<im'+'g src="http://mtrics.cdc.gov/b/ss/cdcgov/1/G.5--FB/s'+s_tm.getTime()+'?[AQB]' +'&j=1.0&[AQE]" height="1" width="1" border="0" alt="" />')
//-->
</script>
<script language="JavaScript" type="text/javascript">
<!--
if(navigator.appVersion.indexOf('MSIE')>=0)document.write(unescape('%3C')+'\!-'+'-')
//-->
</script>
<noscript>
<img src="http://mtrics.cdc.gov/b/ss/cdcgov/1/G.5--NS/0?cl=Session" height="1" width="1" border="0" alt="" />
</noscript>
<!--/DO NOT REMOVE/-->
<!-- END SiteCatalyst/Omniture code here-->
<!-- ####################################  -->
</body>
</html>
